$PFE

Pfizer Inc (PFE) stock rose 3.14% on October 14, outperforming its sector and peers. The increase followed a collaboration announcement with Enodia Therapeutics, upcoming research presentations, and positive earnings revisions. Analysts note technical buy signals but caution about downgrades, COVID-19 revenue declines, and patent expirations. The company's revenue was $62.58B, with a net profit of $7.77B. Analysts' average price target is $29.03.

Pfizer (PFE) offers a 6% dividend yield and potential growth from its expanding portfolio beyond COVID-19. Q2 revenue from launched and acquired products grew 18% YoY, and management raised full-year guidance. The company is focusing on oncology and other areas for future growth, while its dividend provides income for investors.

Five large-cap companies—Altria, AT&T, Enbridge, Pfizer, and Verizon—offer dividends of 5% or more. Verizon and Altria show strong yield and growth, while others face challenges. Altria raised its dividend by 4.7%, and Verizon improved its guidance. Enbridge's payout is affected by currency fluctuations, and Pfizer's dividend remains flat. AT&T has the lowest yield but strong cash flow and buybacks. Investors should watch for dividend changes and operational updates.

Pfizer (NYSE: PFE) will present data from over 50 studies at IDWeek 2026, showcasing advancements in infectious disease prevention and treatment. Key highlights include Phase 2 and 3 results for next-generation vaccines, such as a 25-valent pneumococcal vaccine and a Lyme disease vaccine. The company also shares real-world data on the effectiveness of its RSV and pneumococcal vaccines.

Pfizer will present data from nursing homes on its RSV vaccine, ABRYSVO, after three seasons. The company will also share updates on its pneumococcal, COVID-19, and Lyme disease vaccines at IDWeek 2026. Key studies include Phase 3 results for Lyme vaccine LB6V and real-world effectiveness data for ABRYSVO and PREVNAR 20.

Analysts from Barclays, Wells Fargo, and Chardan Capital provided ratings and price targets for 4D Molecular Therapeutics (FDMT), Pfizer (PFE), and Incyte (INCY). FDMT has a Strong Buy consensus with a $31.25 avg. target. PFE has a Moderate Buy consensus with a $29.62 avg. target. INCY has a Moderate Buy consensus with a $132.58 avg. target.

Pfizer's Phase 3 trial for a maternal GBS vaccine, led by Dr. Joanne Langley, aims to prevent infant infections. GBS causes 150,000 stillbirths/year. The vaccine could reduce cases by over 50%, per WHO. Trial results may lead to availability in a few years, pending approvals.

Pfizer and Enodia Therapeutics partnered in a $500m deal to develop Sec61 inhibitors. Enodia will lead discovery work, while Pfizer handles clinical trials and commercialization. Enodia may receive milestone payments and royalties. The collaboration focuses on Enodia's drug discovery platform targeting harmful proteins.

Pfizer (PFE) and Enbridge (ENB) offer high yields (6.3% and 6.0%, respectively). Pfizer's dividend coverage is thin (89% payout ratio), while Enbridge's cash flow comfortably covers its dividend (1.51x in 2025). Enbridge has higher debt (6.3x net debt/EBITDA vs. Pfizer's 2.0x). Both companies reaffirmed their dividend commitments, with Pfizer's CEO promising to maintain the dividend.

Bristol-Myers Squibb (BMY) and Pfizer (PFE) both aim to replace older drugs. BMY raised its 2026 sales forecast by 5.9% and EPS outlook, driven by Eliquis growth. PFE raised sales forecast by 0.8% but kept EPS outlook unchanged. BMY's newer drugs grew 14% in Q2 2026, while PFE increased R&D spending. BMY trades at a lower P/E multiple but higher growth rate.